Tags: oncology, ADC, Phase 3, lung cancer, pipeline setback, clinical trial failure

Pfizer's Seagen-derived ADC pipeline suffers a setback

By FieldPulse Editorial · June 23, 2026

A phase 3 miss for sigvotatug vedotin gives Pfizer's Seagen-based oncology expansion its first major clinical setback in lung cancer.

Pfizer's Seagen deal has been one of the company's central oncology growth stories, so a phase 3 failure inside that pipeline matters well beyond one trial result.

Pharmaphorum reported that sigvotatug vedotin, an integrin beta-6-directed ADC from the Seagen portfolio, failed to beat docetaxel on overall survival in the phase 3 SigVie-002 study in metastatic non-squamous non-small cell lung cancer.

That is a meaningful setback because sigvotatug vedotin has been framed as one of the assets that could help justify Pfizer's $43 billion Seagen acquisition over time.

According to pharmaphorum, the trial enrolled 703 patients in the second-line-or-later setting.

Pfizer said the study did not improve overall survival on its primary endpoint, which is the core fact that matters for how this asset will now be discussed internally and competitively.

Pfizer did try to preserve some forward momentum.

The company said there were encouraging trends in overall survival and progression-free survival among patients who had received only one prior treatment line, a group that represented roughly two-thirds of the study population.

It also described the safety profile as manageable.

But the commercial takeaway remains narrower than it was before the data: a hoped-for future growth asset now looks less certain in one of the most competitive oncology settings in pharma.

Pharmaphorum also reported that there was no clear relationship between efficacy and IB6 expression, even though integrin beta-6 had attracted attention as a target because it is highly expressed in tumor cells and minimally detectable in healthy lung tissue.

That weakens part of the target-specific story that could have helped position the drug as more clearly differentiated.

For Pfizer oncology teams, the setback removes part of the forward narrative around how the Seagen acquisition would expand the thoracic cancer franchise.

For competitors, it creates more room to question how quickly Pfizer's acquired oncology ass.